Collegium Pharmaceutical (COLL) Research & Development (2014 - 2022)

Collegium Pharmaceutical's Research & Development history runs 9 years deep, the most recent figure standing at $4.0 million for Q1 2022.

• On a quarterly basis, Research & Development rose 35.94% year-over-year to $4.0 million in Q1 2022; TTM through Dec 2022 was $4.0 million, a 57.86% decrease from a year earlier, with the FY2022 full-year figure at $4.0 million, down 57.86% from the prior year.
• Research & Development improved to $4.0 million in Q1 2022 per COLL's latest filing, from $1.6 million in the prior quarter.
• Across five years, Research & Development topped out at $4.0 million in Q1 2022 and bottomed at $1.4 million in Q3 2021.
• The 5-year median for Research & Development is $2.5 million (2019), against an average of $2.5 million.
• Biggest YoY gain for Research & Development was 38.87% in 2021; the steepest drop was 34.91% in 2021.
• Year by year, Research & Development stood at $2.2 million in 2018, then gained by 6.63% to $2.4 million in 2019, then rose by 3.09% to $2.5 million in 2020, then sank by 34.91% to $1.6 million in 2021, then jumped by 147.55% to $4.0 million in 2022.
• Per Business Quant, the three latest COLL Research & Development figures stand at $4.0 million (Q1 2022), $1.6 million (Q4 2021), and $1.4 million (Q3 2021).